TORONTO, May 7, 2018 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical
company specializing in CNS and Cardiovascular markets, announces
that Mr. Ryan C. Lennox has been
named General Counsel. Reporting to the CEO, the General Counsel
role will focus on supporting and enhancing the Company's
acquisition efforts, corporate governance directives and general
legal requirements.
"Ryan fills a strategic role within our organization, providing,
among other things, a key resource in our efforts to identify,
acquire and integrate other promising specialty assets," said
Greg Gubitz, CEO of HLS. "During his
six years at Amgen, he provided senior counsel on a diverse number
of issues in multiple geographic markets, including cross-border
negotiations, and built a deep understanding of the legal landscape
in the Canadian healthcare industry. In addition, at a time when we
have just recently completed our listing on the TSX Venture
exchange, in his role as Corporate Secretary we will also benefit
from his extensive expertise in corporate governance and
compliance."
Since 2012, Mr. Lennox has been Director & Senior Counsel at
Amgen Inc., responsible for all the legal affairs of Amgen's
Canadian affiliate. In more recent years, he had taken on
increasing responsibility at Amgen, including managing the legal
team and affairs of Amgen's Intercontinental Region, comprised of
Canada, Latin America, Turkey, Middle
East and Africa. Mr. Lennox
is called to the bar in both California and Ontario. Prior to joining Amgen, Mr. Lennox
practiced corporate law at McDermott Will & Emery in
San Diego, California and Stikeman
Elliott in Toronto, Ontario, two
international law firms where he advised a wide variety of clients
on corporate finance, M&A, private equity, venture capital and
other types of transactions.
About HLS Therapeutics Inc.
Formed in 2015, HLS is a
specialty pharmaceutical company focused on the acquisition and
commercialization of late stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages.
Forward-Looking Information
This release
includes forward-looking statements regarding HLS and its business.
Such statements are based on the current expectations and views of
future events of HLS's management. In some cases the
forward-looking statements can be identified by words or phrases
such as "may", "will", "expect", "plan", "anticipate", "intend",
"potential", "estimate", "believe" or the negative of these terms,
or other similar expressions intended to identify forward-looking
statements, including, among others, statements with respect to
HLS's pursuit of additional product and pipeline opportunities in
certain therapeutic markets, statements regarding growth
opportunities and expectations regarding financial performance. The
forward-looking events and circumstances discussed in this release
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting HLS, including
risks relating to the specialty pharmaceutical industry, risks
related to the regulatory approval process, economic factors and
many other factors beyond the control of HLS. Forward-looking
statements and information by their nature are based on assumptions
and involve known and unknown risks, uncertainties and other
factors which may cause HLS's actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance or achievements expressed or
implied by such forward-looking statement or information.
Accordingly, readers should not place undue reliance on any
forward-looking statements or information. A discussion of the
material risks and assumptions associated with this release can be
found in the joint information circular of HLS and AMD dated
February 5, 2018 in respect of the
Arrangement, which has been filed on SEDAR and can be accessed at
www.sedar.com. Accordingly, readers should not place undue reliance
on any forward-looking statements or information. Except as
required by applicable securities laws, forward-looking statements
speak only as of the date on which they are made and HLS undertakes
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
SOURCE HLS Therapeutics Inc.